Insight Molecular Diagnostics (IMDX) Assets Average (2016 - 2026)

Insight Molecular Diagnostics has reported Assets Average for 11 years, with the latest figure at $33.1 million in Q1 2026.

• Quarterly Assets Average fell 30.66% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.1 million (down 30.66% YoY) and the FY2025 annual result came in at $30.4 million, down 44.68% from the prior year.
• Assets Average eased to $33.1 million in Q1 2026 per IMDX's latest filing, from $34.8 million in the prior quarter.
• Over five years, Assets Average peaked at $164.2 million in Q3 2022 and troughed at $33.1 million in Q1 2026.
• A 5-year average of $84.3 million and a median of $72.9 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average jumped 65.56% in 2022, then sank 48.5% in 2023.
• Over 5 years, Assets Average stood at $128.7 million in 2022, then sank by 39.22% to $78.2 million in 2023, then plunged by 32.71% to $52.6 million in 2024, then plunged by 33.81% to $34.8 million in 2025, then slipped by 5.04% to $33.1 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $33.1 million, $34.8 million, and $47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.